Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 2/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843154 | 0.97 | NOTUM (0.34) | NOTUMNLRP3DYRK1AGSK3BWNT1 | |
| SCHEMBL211242 | 0.92 | PIN1 (0.36) | NOTUMDYRK1AGSK3BWNT1CTSK | |
| SCHEMBL211244 | 0.92 | PIN1 (0.36) | NOTUMDYRK1AGSK3BWNT1CTSK | |
| SCHEMBL213534 | 0.92 | PIN1 (0.36) | NOTUMDYRK1AGSK3BWNT1CTSK | |
| SCHEMBL211243 | 0.92 | PIN1 (0.36) | NOTUMDYRK1AGSK3BWNT1CTSK | |
| SCHEMBL213535 | 0.92 | PIN1 (0.36) | NOTUMDYRK1AGSK3BWNT1CTSK | |
| SCHEMBL2843062 | 0.90 | PIN1 (0.36) | NOTUMNLRP3DYRK1AGSK3BWNT1 | |
| SCHEMBL2842115 | 0.90 | PIN1 (0.36) | NOTUMNLRP3DYRK1AGSK3BWNT1 | |
| SCHEMBL2873459 | 0.90 | NOTUM (0.36) | NOTUMNLRP3DYRK1AGSK3BWNT1 | |
| SCHEMBL2846571 | 0.90 | NOTUM (0.36) | NOTUMNLRP3DYRK1AGSK3BWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | NOTUM 2164/4885NLRP3 4871/4885DYRK1A 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.